logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Retrophin Raises Offer to Acquire Transcept Pharmaceuticals to $4 Per Share

By  +Follow September 19, 2013 8:51AM
Share:
Tickers Mentioned:

Retrophin, Inc. (RTRX) is not giving up on its pursuit to acquire the shares of specialty drug maker Transcept Pharmaceuticals, Inc. (TSPT) that it does not already own.  Last week, Retrophin delivered a letter to the board of directors of Transcept offering to buy the remaining shares for $3.50 each in cash.  The offer was rejected. 

To defend itself from a hostile takeover, Transcept has adopted a shareholder rights plan, often called a “poison pill,” which keeps a shareholder from acquiring more than 4.99 percent of the company.

On Wednesday, Retrophin bumped the offer up to $4.00 per share, with Retrophin chief executive Martin Shkreli sending a letter to the board members of Transcept.

Transcept is focused on development of neuroscience drugs with its only FDA approval being the oral sleep aid Intermezzo (zolpidem tartrate).  Purdue Pharma holds commercialization and development right for Intermezzo in the U.S.  Royalty revenue for Transcept from Intermezzo in the first six months of 2013 was $1.0 million, up from $500,000 in the year prior period. 

Net loss for the six months ended June 30, 2013 was approximately $17.2 million, or $0.92 per share, versus a net loss of approximately $10.3 million, or $0.67 per share, for the six months of 2012.

Retrophin has four drugs in its pipeline with RE-021 the only one in the clinical stage, being researched in a mid-stage trial for Focal Segmental Glomerulosclerosis, a disease that can cause nephrotic syndrome in children and kidney failure in adults.  The company’s other compounds are targeting hard-to-treat diseases like Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy.

In recent weeks, three major shareholders of Transcept have publicly stated their disapproval of Transcept’s current strategy.  Activist investor Peter Collery of SC Fundamental LLC, which owns a 6.7-percent stake in Transcept, sent a letter to Transcept chief executive, president and director Glenn Oclassen (read the SEC filing) saying that the company needs to use $60 million of its cash to conduct a share repurchase to build value, not pursue “simply wrongheaded,” (but unnamed) projects.

Collery didn’t hold back much in expressing his feelings toward Transept management.  Such as:

“I should note how troubled we are by your presumption that the company’s money is yours to do with as you see fit. You and your fellow directors have a fiduciary duty to company shareholders.”

And...

“I’d like, in closing, also to express my displeasure with the company’s recent grant of nearly 600,000 management stock options with a strike price of $2.93 per share. As described above, the company’s shares may have a current realizable value of $5 or so. Were Transcept to implement a buyback program, that value might rise to $6. Essentially no management skill would be required to realize these values. That the shares trade for less than $3 is a function of shareholders’ distrust of management. It is incredible that management should be granted undervalued stock options as a “reward” for having created that distrust and I would expect that an inquiry into the deliberations surrounding this recent option grant, and particularly, the suitability of the strike price would be quite interesting.”

Roumell Asset Management, LLC, the largest Transcept shareholder at 12.3 percent of the company, has also filed a 13D with the SEC criticizing the management and demanding a share buy-back plan, not an unidentified acquisition.

The new proposal by Retrophin offers to buy Transcept at a 20-percent premium to Tuesday’s closing price.  The price is still lower than the $6 mark that Collery believes can be attained by performing a share repurchase, but this is a little to-may-toes/to-ma-toes because a merged company could benefit similarly, so investors will have to see where the support falls with the new proposal.

“Our proposal represents an attractive premium to Transcept’s trading performance, and we believe that the proposal offers a compelling opportunity for Transcept’s stockholders, particularly in light of Transcept’s risky and controversial acquisition strategy,” stated Martin Shkreli, Chief Executive Officer of Retrophin. “We hope that Transcept’s Board of Directors will respect its stockholders’ wishes and quickly commence discussions with us regarding the proposed transaction.”

Retrophin wants a transaction to be entered into by the end of September.

Shares of TSPT are down about 18 percent in 2013 thanks to a run-up from lows of $2.52 late in August with the acquisition chatter.  At lows, the stock was off about 40 percent.  Shares rose by 8 percent in Wednesday trading to close at $3.59.  In extended trading, shares rose to $3.98.  Retrophin shares edged up about 1 percent on the day to $6.88.  Shares have more than doubled in 2013.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for rtrx
Sludge Reports
20 Sep 14 12:07:29
RT @psuvafan007: 091814 H.R. 5657, Fair Access for Safe and Timely Generics Act of 2014 (“FAST Generics Act”). #REMS $RTRX et al http://t.c…
Stockaholics
20 Sep 14 08:27:59
$ELRA closed up 288.89% on over 315 MILLION Volume! Get our new penny stock picks: http://t.co/qloC4OFNEn $RTRX $CPST $TGTX
Stockaholics
19 Sep 14 23:53:03
$ELRA closed up 288.89% on over 315 MILLION Volume! Get our new penny stock picks: http://t.co/qloC4OFNEn $RTRX $CPST $TGTX
Stock Rocket
19 Sep 14 12:33:58
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/PU7GW934W5 $RTRX $CPST $TGTX
BioInvestor
19 Sep 14 12:04:05
@psuvafan007 @AceOfSpades2007 For $RTRX niche drugs there's no $ to be made if other generics sell at fraction of Retrophin prices
Dr. Zoidberg
19 Sep 14 12:03:05
@AceOfSpades2007 do u think this legislation linked to the recent $RTRX departures?
Dr. Zoidberg
19 Sep 14 11:59:40
@AceOfSpades2007 evidently, any "eligible product developer" can sue license holder 4 injunctive relief and treble damage. $RTRX
Dr. Zoidberg
19 Sep 14 11:53:29
@AceOfSpades2007 As written, seemingly yes. $RTRX
Andrew Colburn
19 Sep 14 11:52:43
@psuvafan007 that would be a pretty big blow to $RTRX's current business model if it passes.
Andrew Colburn
19 Sep 14 11:46:55
RT @psuvafan007: 091814 H.R. 5657, Fair Access for Safe and Timely Generics Act of 2014 (“FAST Generics Act”). #REMS $RTRX et al http://t.c…
Dr. Zoidberg
19 Sep 14 11:45:38
091814 H.R. 5657, Fair Access for Safe and Timely Generics Act of 2014 (“FAST Generics Act”). #REMS $RTRX et al http://t.co/BHtzamSZcr
Sleek Money
19 Sep 14 04:40:12
Insider Buying: Retrophin CEO Purchases 6,000 Shares of Stock $RTRX http://t.co/Sjvl4uAbp4
Stock Rocket
19 Sep 14 02:30:38
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/PU7GW934W5 $RTRX $CPST $TGTX
Stock Rocket
19 Sep 14 00:06:11
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/PU7GW934W5 $RTRX $CPST $TGTX
Stock Rocket
18 Sep 14 21:12:41
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/h5N34SPJ6o $RTRX $CPST $TGTX
WhorableHousewives
18 Sep 14 14:41:43
RT @vram2000: Hope @MartinShkreli keeps a tight leash on sales guys. CTIC Trisenox tale is instructive http://t.co/Bpbwph6ANx $RTRX http://…
US Banking News
18 Sep 14 13:36:31
Insider Buying: Martin Shkreli Acquires 6,000 Shares of Retrophin Stock $RTRX http://t.co/6HaLeDzoh9
US Banking News
18 Sep 14 13:13:28
Retrophin CEO Martin Shkreli Buys $68,760 in $RTRX http://t.co/hP9wuxDIyJ
US Consumer News
18 Sep 14 13:13:27
Retrophin CEO Martin Shkreli Buys $68,760 in $RTRX http://t.co/858ywTsTo8
DumbLuckCapital
18 Sep 14 12:30:40
@scott_matagrano $TRUE and $RTRX
otterom
18 Sep 14 12:06:05
@TheTradeXchange How about all those other calls that, well, didn't do much? Refund policy? $IRET $RTRX
Andrew Colburn
18 Sep 14 11:05:22
@BioDueDiligence @biotechtoreador just the opposite actually. He sold at 15.14, here's the list of his buys $RTRX: http://t.co/GXZIaV7jOC
biotechtoreador
18 Sep 14 10:38:47
@AceOfSpades2007 $RTRX: Way to paint CEO buying shares as negative. If Martin were to walk on water would you complain he can't swim?
US_proptrader
18 Sep 14 10:36:16
$AMKR $AVNR $BKEP $OTIV $RTRX autocharts @ http://t.co/hj7PGeTQk3
US_proptrader
18 Sep 14 10:19:24
$ACHN $AMKR $AVNR $EPIQ $HZNP $KERX $RJET $RTRX $VIMC autocharts @ http://t.co/hj7PGeTQk3
Sludge Reports
18 Sep 14 09:28:56
$RTRX Come on Marty, put some of that vast fortune to work! You wanted everyone else to believe declining Thiola scripts wud bloom.
Andrew Colburn
18 Sep 14 08:58:09
@MartinShkreli buys another few thousand shares. I feel like I've seen this before. Not like he'll sell them at a loss. Oh wait... $RTRX
Edmund Sullivan
18 Sep 14 08:42:48
RT @TheTradeXchange: $RTRX - CEO Buys 6k @$11.4567
George Avidon
18 Sep 14 08:34:06
RT @TheTradeXchange: $RTRX - CEO Buys 6k @$11.4567
Pzaa...Guy
18 Sep 14 08:31:04
$RTRX - Statement of Changes in Beneficial Ownership (4) http://t.co/GjpYFds2Hw
NASDAQ
18 Sep 14 08:31:02
$RTRX - Statement of Changes in Beneficial Ownership (4) http://t.co/ji4pIpMjlX
TradeXchange
18 Sep 14 08:29:36
$RTRX - CEO Buys 6k @$11.4567
zipjet
18 Sep 14 07:31:17
@bradloncar $RWLK went from 12 to 44 now back to 30 - no shares to short at Schwab :-) but you can short $RTRX for 2%
Amel
18 Sep 14 07:18:38
@zerosum24 You are thinking of $RTRX
Dr. Zoidberg
18 Sep 14 07:14:16
RT @SludgeReports: $RTRX Jeff Paley, Director, dumped 28% on 8-14-2014, minutes after a Marty 'awesome stuff' tweet. Guess that was the wr…
Dr. Zoidberg
18 Sep 14 07:14:07
RT @BioRunUp: $RTRX down 10% on CFO resignation (Marc Panoff) AND board member Jeffrey Paley stepping down. (updated tweet)
FonsieTrader
18 Sep 14 04:37:10
Moved Lower Bollinger Band 3/3 $LNKD $MKC $OI $PBI $RBC $RDC $RTRX $SAP $SBGL $SPNC $SWAY $SWFT $TRI $UL $URBN $WY http://t.co/2COso0p7PT
Stock Rocket
17 Sep 14 23:32:20
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/PU7GW934W5 $RTRX $CPST $TGTX
chartguy89
17 Sep 14 22:47:24
RTRX 11.46 Stock Charts $RTRX Retrophin Inc. (NASDAQ) Last Updated: 09/18/2014 00:47:31 RTRX Stock Chart - 1 M http://t.co/NF7B7SVGFv
Nyjohnnygray
17 Sep 14 19:52:51
@SludgeReports $rtrx I remember this tweet - was clear it was a pump This stock is for riding the coattails of crooks
Jamie Rushton
17 Sep 14 19:34:01
@DK2939 @MartinShkreli lol... Exactly! ~80% of the current number have been hired in the last ~9months! So the 3yr thing is BS. $RTRX
nixon786
17 Sep 14 18:51:04
Guess - $RTRX buys $MRNA
Pzaa...Guy
17 Sep 14 17:02:07
$RTRX - Harwood Feffer LLP Announces Investigation of Retrophin, Inc. http://t.co/h1HsxQmCqe
OTC Alerts
17 Sep 14 16:10:08
$RTRX received a new alert.See why at http://t.co/FwU0sYdHLW $MSEZ #Penny #pennystocks #PinkSheet #OTC #OTCBB #stocks #stock 168
Equities.com
17 Sep 14 16:06:00
RETROPHIN INC (RTRX) Drops 8.25% on September 17 $rtrx http://t.co/0ZiM2kq1tL
Stock Rocket
17 Sep 14 15:10:58
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/h5N34SPJ6o $RTRX $CPST $TGTX
Sludge Reports
17 Sep 14 14:52:39
$RTRX remember this tweet from last month? Director selling http://t.co/3BsiROQC3I
John Hall
17 Sep 14 14:35:39
@SludgeReports @86753O wasn't meant for you. Sorry do the schrapnel $RTRX
Stock Horizon LLC
17 Sep 14 13:00:06
Alert results: http://t.co/BAmKc1sy6T $CNCE +4% $IFON +22% $NETE +21% $OTIV +9% $RTRX +1% $SCOK +4% $SINO +20% $VHC +10%
Stock Rocket
17 Sep 14 12:42:12
$NETE Gained 551.93% In The Past 6 Weeks! Major News: http://t.co/PU7GW934W5 $RTRX $CPST $TGTX
				
				
By  +Follow September 19, 2013 8:51AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.